ArticlePolymers2025
Preparation of a Macromolecular Flame Retardant with a Phosphine Oxide Structure and Its Application in Polyamide 6.
Article in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In this study, a novel macromolecular flame retardant (MFR) with a phosphine oxide structure is successfully synthesized to improve the flame retardancy of polyamide 6 (PA6). Following this, the flame-retardant polyamide 6 (FR-PA6) is prepared via melt blending the MFR with PA6. Results indicate that the introduction of MFR has little effect on the melting and crystallization temperature of FR-PA6. While it slightly reduces the thermal stability of PA6, MFR significantly enhances its flame retardancy. The limiting oxygen index of FR-PA6 increases from 21.8% to 28.2%, and it successfully passes the UL-94 V-0 rating when it contains 0.5 wt% of phosphorus. Compared with pure PA6, the av-EHC of FR-PA6 is reduced by 32.2% and the SEA is increased by 66.7%. The MFR showed a flame-retardant mechanism in both the gas phase and the condensed phase. In the gas phase, the decomposition of MFR releases phosphorus-containing free radicals to interrupt the combustion chain reaction and reduces the concentration of the combustible caprolactam. In the condensed phase, the MFR promotes faster formation of melt droplets during combustion, taking heat away from the burning PA6 timely.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.